Italy Archives

News and Trends 11 Jun 2015

Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

Cassiopea, Cosmo Pharmaceutical’s spin-out, will be listed on the Swiss Stock Exchange. Cosmo Pharmaceutical plans to reduce its current 97% shareholding to below the 50% bar. The majority shareholder will give away the control of its subsidiary in order to have enough cash after the end of its Phase III ACNE-treatment, currently running in the US and […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 May 2015

NewCo, the union of Sorin and Cyberonics

[UPDATE 27/05/2015]: Sorin’ shareholders approved the merger with Cyberonics in an Extraordinary Meeting. Sorin and Cyberonics, agreed on a merger plan to create a new global leader in medical technologies with a combined equity value of approximately €2.4Bn based on the closing price of Sorin and Cyberonics shares of 25th February. Sorin and Cyberonics will combine […]

May 27, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important acquisition, Baxter is reinforcing its oncology presence by owning Oncaspar, a treatment against acute lymphocytic leukemia. Oncaspar is the only FDA-approved pegylated formulation of L-asparaginase, the enzyme that depletes the aminoacid asparagine. Whilst normal cells can produce asparagine, leukemic cells […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 Feb 2015

GNA Biosolutions Leads the Consortium for Ultra-Fast Detection of Ebola

The ultra-fast diagnostic instruments developer, GNA Biosolutions (GNA), started the FILODIAG (Filovirus Diagnostics) project for developing a high-speed Ebola detection system based on GNA’s novel Laser PCR technology. There is an urgent need for fast and accurate diagnostic tests in the current and any future Ebola crisis. The rapid diagnosis of Ebola during early and […]

February 20, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 12 Feb 2015

Neurostimulation, an Innovative Approach to Treat Heart Failure

The revolutionary Equilia system, meant to treat heart failure, has been successfully implanted for the first time in a clinical study . The developer of the system, Sorin Group, is an Italian medical device company, leader in the treatment of cardiovascular diseases. Heart failure is a chronic progressive disease in which the heart can no longer […]

February 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Jan 2015

Italian Genenta Science’s Original Strategy to Treat Cancer

Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response to therapies. It stimulates tumor growth, supports angiogenesis and tissue remodeling, as well as neutralizes host immunity. Genenta Science is using this mechanism, which is certainly a promising area of cancer biology for the identification of new therapeutic targets. In […]

January 27, 2015 - 2 minutesmins - By Lourdes Riquelme

LoneStar Heart Hydrogel advanced heart attacks

News and Trends 4 Oct 2014

A Hydrogel to treat Advanced Heart Failure in Europe

LoneStar Heart, Inc. announced that it received the CE Mark (European Conformity) for its Algisyl-LVR® hydrogel implant,a product for the treatment of advanced heart failure (HF). The CE Mark indicates a product’s compliance with European Union legislation and that it can be sold throughout the European Economic Area. Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is […]

October 4, 2014 - 2 minutesmins - By Julie Lellouche

Kao research identifies natural enzyme to produce sustainable surfactants strict xxl

News and Trends 24 Sep 2014

Natural Cosmetics thanks to Enzymes?

A 7 million euros European-funded project has been launched with the intention of replacing chemical cosmetic production techniques with eco-friendly alternatives. This is the OPTIBIOCAT project which wants to provide technical improvement to the natural cosmetics sector, required to satisfy consumer demand for natural and ecological products. Building on a diverse consortium of 16 partners from […]

September 24, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us